GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (GREY:OBSEF) » Definitions » Price-to-Free-Cash-Flow

ObsEva (ObsEva) Price-to-Free-Cash-Flow : N/A (As of May. 05, 2024)


View and export this data going back to 2017. Start your Free Trial

What is ObsEva Price-to-Free-Cash-Flow?

As of today (2024-05-05), ObsEva's share price is $0.005. ObsEva's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.29. Hence, ObsEva's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for ObsEva's Price-to-Free-Cash-Flow or its related term are showing as below:

OBSEF's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 31.89
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

ObsEva's Free Cash Flow per Share for the three months ended in Dec. 2022 was $0.07. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.29.


ObsEva Price-to-Free-Cash-Flow Historical Data

The historical data trend for ObsEva's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Price-to-Free-Cash-Flow Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only - - - - -

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ObsEva's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, ObsEva's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ObsEva's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ObsEva's Price-to-Free-Cash-Flow falls into.



ObsEva Price-to-Free-Cash-Flow Calculation

ObsEva's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.005/-0.293
=N/A

ObsEva's Share Price of today is $0.005.
ObsEva's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.29.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

ObsEva  (GREY:OBSEF) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


ObsEva Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ObsEva's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (ObsEva) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.
Executives
William Michael Brown officer: Chief Financial Officer 910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Anne Vanlent director C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Brian O'callaghan director, officer: Chief Executive Officer 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ernest Loumaye director C/O OBSEVA SA, CHEMIN DES AULX, 12, OLAN-LES-OUATES, GENEVA V8 1228
Catarina Edfjall director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 0000000000
Annette Clancy director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228
Stephanie Clare Brown director C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228

ObsEva (ObsEva) Headlines

From GuruFocus